Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2024; 13(02): 126-131
DOI: 10.1055/s-0043-1761441
Original Article
Hematological Malignancie

Cytogenetic Alterations and Correlation with Age and Gender in Patients of Multiple Myeloma: A Study from a Tertiary Care Center in Eastern India

Karuna Jha
1   Department of Clinical Hematology, Institute of Hematology and Transfusion Medicine, Medical College, Kolkata, West Bengal, India
,
Sandeep Saha 
1   Department of Clinical Hematology, Institute of Hematology and Transfusion Medicine, Medical College, Kolkata, West Bengal, India
,
Maitreyee Bhattacharyya 
1   Department of Clinical Hematology, Institute of Hematology and Transfusion Medicine, Medical College, Kolkata, West Bengal, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Zoom Image
Karuna Jha

Background Multiple myeloma is a cytogenetically heterogeneous, evolving, and incurable disease. Differences in prevalence of myeloma already exist in Indian subcontinent as compared with Western world countries. This study attempts to investigate differences in incidence of cytogenetic abnormalities (CA) in Eastern Indian patients and study differences in incidence with respect to age and gender.

Materials and Methods Interphase fluorescence in situ hybridization (FISH) was applied on purified plasma cells of 280 newly diagnosed myeloma cases using specific probes.

Statistical Analysis Data was analyzed using SPSS software version 25.

Results Note that 51.07% patients were FISH positive. Del13q was the most common CA. Significant association of del 13q with t(4;14), del 17p, and gain of 1q was seen. The frequencies of FISH positive and negative groups differed in the different age groups; higher number of cases in 41 to 50 years group in FISH positive group (p < 0.05) and lower number of cases in FISH positive group in 61 to 70 years (p < 0.05) as compared with FISH negative group. Del 17p had higher number of cases in age group 41 to 50 years and 51 to 60 years as compared with other age groups. Incidence of t(11;14) was in 5th to 7th decade while del 13q and t(4;14) had the widest range of age at presentation. Gender disparities were seen in high-risk cytogenetics like del 17p and 1q gain.

Conclusion The differences in incidence rate of CAs per se in myeloma cases diagnosed in Indian subcontinent and the differences in incidence with respect to age and gender warrant further multicentric studies.

Keywords

myeloma - FISH - cytogenetic aberrations - age - gender

Authors' Contributions

K.J., D.M.: Concepts design, definition of intellectual content, literature search, data analysis, manuscript preparation, and manuscript editing. S.S., D.M.: Literature search, data analysis, manuscript preparation, and manuscript editing. M.B., D.M.: Concepts design, definition of intellectual content, manuscript preparation, and manuscript editing.




Publication History

Article published online:
12 February 2024

© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Prideaux SM, Conway O'Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol 2014; 2014: 864058
    CrossrefPubMedGoogle Scholar
  • 2 Yuregir OO, Sahin FI, Yilmaz Z, Kizilkilic E, Karakus S, Ozdogu H. Fluorescent in situ hybridization studies in multiple myeloma. Hematology 2009; 14 (02) 90-94
    CrossrefPubMedGoogle Scholar
  • 3 Fonseca R, Bergsagel PL, Drach J. et al; International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23 (12) 2210-2221
    CrossrefPubMedGoogle Scholar
  • 4 Kurahashi S, Sawamoto A, Sugimoto T. et al. Frequency and prognostic value of chromosome abnormalities in multiple myeloma [in Japanese]. Rinsho Ketsueki 2007; 48 (11) 1455-1461
    PubMedGoogle Scholar
  • 5 Li S, Lim HH, Woo KS, Kim SH, Han JY. A retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: a single center study in Korea. Blood Res 2016; 51 (02) 122-126
    CrossrefPubMedGoogle Scholar
  • 6 Hamdaoui H, Benlarroubia O, Ait Boujmia OK. et al. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients. Mol Genet Genomic Med 2020; 8 (09) e1363
    CrossrefPubMedGoogle Scholar
  • 7 Huang SY, Yao M, Tang JL. et al. Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. Ann Oncol 2005; 16 (09) 1530-1538
    CrossrefPubMedGoogle Scholar
  • 8 Abdallah N, Rajkumar SV, Greipp P. et al. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J 2020; 10 (08) 82
    CrossrefPubMedGoogle Scholar
  • 9 Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 2014; 28 (02) 398-403
    CrossrefPubMedGoogle Scholar
  • 10 Udupa CBK, Udupa KS, Pai A, Sherigar P. Cytogenetics and Revised International Staging System (R-ISS): risk stratification in multiple myeloma - a retrospective study in Indian population. Iran J Pathol 2020; 15 (03) 182-188
    CrossrefPubMedGoogle Scholar
  • 11 Royal AP, Lubna SS, Angel PB. et al. Chromosomal aberrations in multiple myeloma: a study on Indian population. Acta Med Int 2018; 5: 74-78
    CrossrefGoogle Scholar
  • 12 Dhiman P, Goel S, Samal P. et al. FISH Analysis in Multiple Myeloma - a Retrospective Study from India. Blood 2016; 128 (22) 5646
    CrossrefGoogle Scholar
  • 13 Govindasamy P, Pandurangan P, Tarigopula A, Mani R. R Samuel C, Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India. Asian Pac J Cancer Prev 2019; 20 (01) 235-241
    CrossrefPubMedGoogle Scholar
  • 14 Kadam Amare PS, Jain H, Nikalje S. et al. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India. Indian J Med Res 2016; 144 (04) 536-543
    PubMedGoogle Scholar
  • 15 Lakshman A, Painuly U, Rajkumar SV. et al. Natural history of multiple myeloma with de novo del(17p). Blood Cancer J 2019; 9 (03) 32
    CrossrefPubMedGoogle Scholar
  • 16 Gadhia PK, Vaniawala S. Cytogenetics and FISH studies in multiple myeloma-a retrospective study from Western India. Am J Curr Biol 2015; 2 (01) 1-7
    Google Scholar
  • 17 Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. Cells 2021; 10 (02) 336
    CrossrefPubMedGoogle Scholar
  • 18 Kyle RA, Gertz MA, Witzig TE. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78 (01) 21-33
    Google Scholar
  • 19 Boyd KD, Ross FM, Chiecchio L. et al. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2011; 20 (08) 1703-1707
    CrossrefPubMedGoogle Scholar
  • 20 Fonseca R, Blood E, Rue M. et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101 (11) 4569-4575
    Google Scholar
  • 21 Liebisch P, Wendl C, Wellmann A. et al. High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis. Leukemia 2003; 17 (12) 2535-2537
    CrossrefPubMedGoogle Scholar
  • 22 Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82 (01) 41-49
    CrossrefPubMedGoogle Scholar
  • 23 Wu KL, Beverloo B, Lokhorst HM. et al; Dutch-Belgian Haemato-Oncology Cooperative Study Group (HOVON), Dutch Working Party on Cancer Genetics and Cytogenetics (NWCGC). Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 2007; 136 (04) 615-623
    CrossrefPubMedGoogle Scholar
  • 24 Schmidt TM, Barwick BG, Joseph N. et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J 2019; 9 (12) 94
    CrossrefPubMedGoogle Scholar